Home›Stock Screener›Gland Pharma

Gland Pharma Share Price Today | Stock Price & Gland Pharma Share Screener

GLAND Pharmaceuticals & Biotechnology
Live Share Price NSE
₹3230.50
▼ -17.90 (-0.55%)
2026-11-18 00:00:00
Live Share Price BSE
₹3229.80
▼ -19.45 (-0.60%)
2026-11-18 00:00:00

As of November 18, 2026, the live Gland Pharma share price (NSE: GLAND) is ₹3,230.50 on NSE and ₹3,229.80 on BSE, down 0.55% from the previous close, with shares trading between ₹3,208.70 and ₹3,278.00 in today's trading session, and a 52-week range of ₹1,596.80–₹3,385.90. Track Gland Pharma market worth to gauge the company's total market size. Use the Gland Pharma stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Gland Pharma opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹1,903 and net income of ₹291, with EBITDA of ₹553, an operating margin of 26.0% and a profit margin of 15.3%.

Gland Pharma Market Cap ₹53,602.13 Cr.
GLAND P/E Ratio (TTM) 45.10
Gland Pharma P/B Ratio 5.22
EPS (TTM) ₹62.35
Dividend Yield 0.59%
Debt to Equity 0.03
GLAND 52 Week High ₹3385.90
Gland Pharma 52 Week Low ₹1596.80
Operating Margin 26.00%
Profit Margin 15.29%
GLAND Revenue (TTM) ₹1,903.00
EBITDA ₹553.00
Net Income ₹291.00
Total Assets ₹12,511.00
Total Equity ₹10,358.00

Gland Pharma Share Price Chart

Track the current stock price of Gland Pharma with an interactive chart. Analyse GLAND share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Gland Pharma stock quote in one place.

The quote of ₹3,230.50 sits between the 52-week low of ₹1,596.80 and the 52-week high of ₹3,385.90, and the latest session moved -0.55% from the previous close.

Gland Pharma Company Profile - Fundamental Screener

Screen Gland Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for GLAND shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, with SRINIVAS SADU listed as chairperson or CEO, and it trades under ISIN INE068V01023.

Business Overview

Gland Pharma Limited is an Indian generic injectables manufacturer specializing in sterile injectables, oncology, and ophthalmic products. Founded in 1978, the company operates primarily on a B2B model, selling products in over 60 countries. It has 8 manufacturing facilities in India, including 4 for finished formulations and 3 for APIs....more

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

Chairperson/CEO SRINIVAS SADU
ISIN INE068V01023

Gland Pharma Balance Sheet Screener

Screen GLAND balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹12,511, up from ₹11,225 in 2025.

Latest statistics put total assets at ₹12,511 and shareholder funds at ₹10,358, with a leverage ratio of 0.03.

Item 2026 2025 2024 2023 2022 2021 2020

Assets

Total Assets 12,511 11,225 10,661 8,778 7,834 6,496 4,086
Current Assets 0 0 0 0 0 0 0
Fixed Assets 4,492 4,147 3,947 1,571 1,502 954 968

Liabilities

Total Liabilities 0 0 0 0 0 0 0
Current Liabilities 545 509 539 90 94 80 81
Non-Current Liabilities 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 10,358 9,151 8,724 7,959 7,158 5,903 3,646
Share Capital 17 17 17 17 16 16 16
Reserves & Surplus 10,342 9,134 8,707 7,942 7,141 5,887 3,631

Gland Pharma Income Statement Screener - Profit & Revenue Analysis

Screen Gland Pharma income statement and profit fundamentals. Analyze GLAND quarterly results. Gland Pharma reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Sept, revenue was ₹1,903 and net profit was ₹291, equal to earnings per unit of ₹17.62, at an operating margin of 26%.

In that period expenses were ₹1,350, interest cost ₹7 and tax ₹140. The next period listed, 2026-Jun, shows revenue of ₹1,862 and net profit of ₹317.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun 2024-Mar 2023-Dec 2023-Sept 2023-Jun 2023-Mar

Revenue and Expenses

Revenue 1,903 1,862 1,854 1,759 1,571 1,563 1,469 1,443 1,466 1,453 1,580 1,583 1,427 1,246 824
Expenses 1,350 1,311 1,230 1,285 1,173 1,138 1,077 1,024 1,109 1,137 1,179 1,189 1,049 915 673

Operating Costs and Margins

EBITDA 553 551 625 474 398 425 392 418 357 316 401 394 377 332 151
Operating Profit % 26.00% 27.00% 29.00% 24.00% 21.00% 24.00% 24.00% 26.00% 21.00% 19.00% 23.00% 23.00% 24.00% 24.00% 14.00%
Depreciation 115 111 109 108 106 101 96 96 94 92 93 105 81 65 38
Interest 7 4 10 4 8 12 7 23 6 6 10 5 6 5 2

Profit and Earnings

Profit Before Tax 431 435 506 362 284 313 288 299 257 218 298 283 290 261 111
Tax 140 118 139 101 100 97 102 95 93 75 106 91 96 67 33
Net Profit 291 317 367 262 184 216 187 205 164 144 192 192 194 194 79
EPS 17.62 19.23 22.26 15.87 11.15 13.08 11.32 12.42 9.93 8.73 11.68 11.65 11.78 11.79 4.78

Gland Pharma Cash Flow Screener - Liquidity Fundamentals

Screen GLAND cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹1,031, and net cash flow was an inflow of ₹803.

Over the same period, investing activities provided ₹189 and financing activities used ₹417.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March

Cash from Operations and Investing

Operating Activities 1,031 915 997 364 791 605 701
Investing Activities 189 1,718 -1,749 1,211 -999 -1,520 -761

Financing and Net Cash

Financing Activities -417 -434 -799 15 35 1,239 -7
Net Cash Flow 803 2,199 -1,552 1,590 -174 323 -67

Gland Pharma Shareholding Pattern Screener

See Gland Pharma shareholding pattern with promoter, FII, and DII holdings. Check Gland Pharma promoter holding and ownership changes for GLAND on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 51.83%, foreign institutions 7.30%, domestic institutions 33.35% and the public 2.53%, spread across 91,500 shareholders.

The shareholder count was 91,500 in 2026-Mar, compared with 108,266 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar

Promoter Holding

Promoter Holding 51.83% 51.77% 45.75% 51.83% 51.83% 51.83% 51.83% 57.86%

Institutional Investors

FII Holding 7.30% 8.74% 10.36% 6.90% 7.39% 7.91% 7.58% 3.59%
DII Holding 33.35% 30.44% 33.21% 33.27% 32.85% 32.64% 32.98% 25.23%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 2.53% 3.50% 4.63% 2.99% 2.91% 2.57% 2.57% 3.28%
Other Holding 4.98% 5.55% 6.03% 5.01% 5.02% 5.06% 5.04% 10.04%
Shareholder Count 91,500 108,266 125,667 113,788 110,671 97,151 94,578 122,375

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Gland Pharma. Gland Pharma dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹20.00 per unit for 2026-March, a yield of 0.59%, compared with ₹18.00 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹20.00, ₹18.00 and ₹20.00 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹20.00 0.59%
2025-March ₹18.00 1.06%
2024-March ₹20.00 1.26%
2023-March ₹0.00 0.00%
2022-March ₹0.00 0.00%
2021-March ₹0.00 0.00%
2020-March ₹0.00 0.00%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%

Gland Pharma Stock Index Membership - Nifty & Sensex

See which indices include Gland Pharma stock. Check GLAND index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 19 indices, including BSE 1000.

Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX BSE500, BSE INDEX BSEIPO.

Complete Index List

BSE 1000
BSE INDEX BSE HC
BSE INDEX BSE500
BSE INDEX BSEIPO
BSE INDEX LMI250
BSE INDEX MID150
BSE INDEX MIDCAP
BSE INDEX MSL400
NIFTY 500
NIFTY LARGEMID250
NIFTY MIDCAP 150
NIFTY MIDSML 400
NIFTY MIDSML HLTH
NIFTY MNC
NIFTY PHARMA
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MULTICAP

Gland Pharma Market Events Screener - Corporate Actions

Get Gland Pharma corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Gland Pharma stock events that may affect GLAND share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 6, 2026, with a record date of November 6, 2026.

It is followed by Annual General Meeting dated August 25, 2026 and Dividend dated August 11, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-06 2026-11-06 Quarterly Result Announcement NA 4.15%
2026-08-25 2026-08-25 Annual General Meeting NA 47.59%
2026-08-11 2026-08-11 Dividend ₹ 20.00 /share 40.52%
2026-08-10 2026-08-10 Quarterly Result Announcement NA 9.37%
2026-05-15 2026-05-15 Quarterly Result Announcement NA 5.78%
2026-01-28 2026-01-28 Quarterly Result Announcement NA -1.36%
2025-11-03 2025-11-03 Quarterly Result Announcement NA 0.59%
2025-08-28 2025-08-28 Annual General Meeting NA 29.92%
2025-08-14 2025-08-14 Dividend ₹ 18.00 /share 31.41%
2025-08-05 2025-08-05 Quarterly Result Announcement NA -0.90%
2025-05-20 2025-05-20 Quarterly Result Announcement NA 4.61%
2025-02-03 2025-02-03 Quarterly Result Announcement NA -8.51%
2024-11-04 2024-11-04 Quarterly Result Announcement NA -1.82%
2024-08-30 2024-08-30 Annual General Meeting NA 2.71%
2024-08-16 2024-08-16 Dividend ₹ 20.00 /share 8.78%

Gland Pharma Competitors Screener - Peer Stocks Comparison

Screen GLAND competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 448,676 40.80 61,674 12.69% 11,565 60.46
Divis Laboratories 295,997 87.70 11,067 13.95% 2,568 68.76
Torrent Pharmaceuticals 177,586 85.00 13,886 20.34% 2,138 47.23
Laurus Labs 126,325 89.90 6,868 22.01% 890 57.04
Zydus Life Science 120,119 27.60 27,658 17.64% 5,026 55.91
Dr Reddys Laboratories 115,854 41.80 35,059 3.90% 4,158 71.26
Cipla 112,131 39.50 29,045 2.24% 3,870 53.06
Mankind Pharma 107,805 47.90 14,636 14.85% 1,938 61.37
Aurobindo Pharma 103,229 25.80 34,145 5.56% 3,503 60.39
Lupin 89,172 17.30 29,039 26.75% 5,356 39.39

Gland Pharma Company Announcements - News & Reports Screener

Screen GLAND latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated .

The next most recent announcements are dated November 17, 2026 and November 17, 2026.

Date Update Actions
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-11-17 Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS -
2026-11-17 Grant Of Options To Purchase Securities -
2026-11-13 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-11-13 Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-11-10 Announcement under Regulation 30 (LODR)-Change in Management -
2026-11-08 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-11-08 Shareholder Meeting / Postal Ballot-Scrutinizer"s Report -
2026-11-08 Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot -
2026-11-08 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-11-06 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-11-06 Unaudited Financial Results For The Quarter And Half Year Ended September 30 2026 -
2026-11-06 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-11-06 Board Meeting Outcome for Outcome Of Board Meeting - November 06 2026 -
2026-11-03 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-10-30 Announcement under Regulation 30 (LODR)-Change in Management -
2026-10-23 Conclusion Of USFDA Unannounced Inspection At Companys Formulation Facility At Dundigal Hyderabad -
2026-10-21 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-21 Board Meeting Intimation for Declaration Of Unaudited Financial Results For The Quarter And Half Year Ended September 30 2026 -
2026-10-12 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹3,230.50, within a 52-week range of ₹1,596.80 to ₹3,385.90. The P/E ratio is 45.10 and the P/B ratio is 5.22, with earnings per unit of ₹62.35. Market capitalisation stands at ₹53,602.13 Cr and the dividend yield is 0.59%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 18, 2026. This page covers 7 balance sheet periods, 15 income statement periods, 7 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.